Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 6,93 € (+160,53 %). Medianen er 6,93 € (+160,53 %).
| Køb |
1 |
| Behold |
0 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
SeaStar Medical sponsors KidneyBee Summit and webinar on QUELIMMUNE for children with acute kidney failure
SeaStar Medical announces sponsorship support for the KidneyBee Summit 2026 at Children’s Hospital Colorado and a continuing-education webinar on August 11, 2026. The webinar covers the QUELIMMUNE therapy (SCD-PED) for treating critically ill children with acute kidney failure and sepsis; speakers include Dr. Stuart Goldstein, Dr. Stephen Gorga and Dr. Kevin Chung. QUELIMMUNE was approved in February 2024 via a Humanitarian Device Exemption; studies and registry data showed survival rates of about 71–77% in treated pediatric patients. The stock (NASDAQ:ICU) has risen nearly 100% year-to-date and trades at $4.79 with a market capitalization of $19.3 million. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 538,87 t | 87,91 % |
| Bruttofortjeneste | 491,55 t | 86,29 % |
| Nettoresultat | -3,27 mio. | 92,42 % |
| EBITDA | -3,25 mio. | 92,15 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 7,45 mio. € |
Antal aktier | 2,84 mio. |
Højeste/laveste i 52 uger | 10,83 € - 1,79 € |
| Udbytte | Nej |
Beta | -1,03 |
P/E (PE Ratio) | -0,77 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 2,88 |
P/S (PS Ratio) | 5,02 |
Virksomhedsprofil
| Navn | SeaStar Medical Holding Corp Ordinary Shares |
| CEO | Eric Schlorff |
| Medarbejdere | 18 |
